Abstract: A C-Band Disinfector disinfects objects placed within the device by subjecting the objects to closed-loop emissions of UV-C radiation. UV-C sensors measure reflected UV-C radiation and control the period of operation of the device. In an additional embodiment, UV-C radiation is transmitted by fiber-optic cable to a particular area of an object to be disinfected. After the prescribed dose is applied, the fiber-optic cable is moved to a new area of the object, and the UV-C disinfection process continues until all areas of the object have been disinfected by exposure to the prescribed dose of the UV-C radiation.

Abstract: A self-sterilizing gripping or handle apparatus. The apparatus and method of the invention have to do with sterilizing a gripping surface with germicidal ultraviolet light. Embodiments of an apparatus are disclosed which provide for periodic and repeated exposure of a gripping surface to the UV radiation. The gripping surface may be incorporated into a handle, so that the handle remains relatively germ-free between uses by individuals.

Abstract: A portable micro-organism inactivation system comprising: a casing mounting, a UV radiation source, a pump, and releasable tube support for supporting an elongate tube to define a flow path extending therethrough which is substantially free of substantial discontinuities are provided by the present invention. The elongate tube has a first portion and a second portion wherein the first portion has a UV-transparent wall. The first portion extends in close proximity to the UV radiation source within an irradiation zone thereof while the second portion is interfaced with the pump for pumping of fluid through the system so that substantially the whole of said individual fluid unit is exposed to a similar micro-organism inactivating level of UV-irradiation, while minimizing damage to the desired components thereof. The invention also provides a method of micro-organism inactivation in a fluid using a system of the invention.

Abstract: A method and system for the extracorporeal treatment of blood to remove fluid from the fluid overloaded patient is disclosed that non-invasively measures an oxygen level in the venous blood. The oxygen blood level is used to detect when hypotension is about to occur in a patient. The oxygen level measurements are used as feedback signals. These feedback signals are applied to automatically control the rate of fluid extraction to achieve the desired clinical outcome and avoid precipitating a hypotensive crisis in the patient.

Abstract: Particles dispersed in a liquid are assembled in a configuration in which all the particles lie in the same plane, and the assembled particles are processed while in that configuration. The assembled particles can for example be simultaneously exposed to electromagnetic radiation which elicits from the particles a response which provides information about the particles. The particles can for example be cells, cell fragments, or analyte-bearing beads of the type conventionally analyzed in a cytometer.

Abstract: Novel nanowell microarrays are disclosed in optical contact with polymer waveguides wherein evanescent field associated with lightwaves propagated in the waveguide excite target substances in the nanowells either by a common waveguide or by individual waveguides. Fluid samples are conveyed to the nanowells by means of microfluidics. The presence of the target substances in fluid samples is detected by sensing fluorescent radiation generated by fluorescent tag bound to the target substances. The fluorescent tags generate fluorescent radiation as a result of their excitation by the evanescent field. One or more PMT detectors or a CCD detector are located at the side of the waveguide opposite to the nanowells. Fluorescent radiation is detected due to its coupling with the waveguide or its emission through the waveguide.

Abstract: The surface of a needle for collecting samples is coated with a coating material lower in chemical activity than a base metal of the needle. More specifically, the surface of the needle may be coated with a layer of gold or platinum. Alternatively, the surface of the needle may be coated with a synthetic resin coating of, for example, PEEK which is superior in chemical resistance. As a result, it is possible to obtain a practically sufficient antifouling effect even on contamination coming from chemical adsorption. Such contamination could not be removed sufficiently only by related-art measures against physical contamination. Thus, it is possible to provide an automatic sampler which can perform highly sensitive analysis.

Abstract: A volume adjustable pipette, comprising a plunger mounted for movement in a housing to and from a stop to aspirate a fluid into and dispense the fluid from a tip extending from the housing. An axially moveable volume setting member in the housing defines the stop and a volume setting for the pipette and is axially moveable by a user turnable volume setting member. Turning of the volume adjusting member also controls a coarse volume setting means and a fine volume setting means, the course volume setting means being responsive to a relatively small turning of the volume adjusting member for moving the volume setting member a relatively large axial distance and the fine volume setting means being responsive to a relatively large turning of the volume adjusting member for moving the volume setting member a relatively small axial distance.

Abstract: A cartridge device containing UVC for air disinfection that comprises individual ultraviolet bulb, HEPA/Carbon filter, LED for detection of replacement, ballast and electrical components; cartridge is plugged into a backplane which allows for easy installation and servicing of all components. The backplane powers the device and can be encased in various configurations which can be used in multiple applications, including portable and permanent air treatment devices.

Abstract: A fan type chemical diffusing apparatus includes an apparatus main body having an air inlet and an air outlet, a fan type blower disposed in the apparatus main body, and an active ingredient impregnated body or mass for containing an active ingredient. The fan type blower includes a fan casing, a motor, and a fan including a rotary disk and a plurality of blades fastened to a peripheral portion of the rotary disk and provided with a hollow space that is on an interior of the fan with respect to the blades. The fan type blower is operable to send air from the air inlet through the hollow space and out through the air outlet.

Abstract: A process of extracting halogenated organic compounds, and particularly PCBs, from soil, sediment, slurry, sludge and dehalogenating the compounds contacts a contaminated soil sample with an extraction medium of a mixture of an alkane and a water miscible alcohol. The organic compounds dissolve in the extraction medium which is separated from the soil by passing water upwardly through the soil. The extraction medium floats to the surface of the water and is separated. Thereafter, the extraction medium containing the halogenated organic contaminants is subjected to ionizing radiation to radiolytically dehalogenate the compounds.

Abstract: The compact chemical reactor includes a first substrate, a second substrate attached to the first substrate. A micro flow path is defined between the first substrate and the second substrate. A thin film heater provided in the flow path.

Abstract: Selective extraction of a metal anion complex, such as a platinum-group metal halide, from an aqueous solution containing other metal anions or anion complexes, by contacting the solution with a diquaternary ammonium salt having two quaternary nitrogens spaced at a distance less than about 10 ?, selectively binding the metal anion complex to the diquaternary ammonium salt to form an organo-metallic complex, and separating the organo-metallic complex from the solution. Alternatively, the diquaternary ammonium salts may be adsorbed or chemically bonded to a substrate, and the metal anion complex-containing solution passed over the substrate. Preferably, the two quaternary nitrogens are spaced a distance apart that is complementary to the ionic diameter of the target metal anion complex.

Abstract: Spent, acidic solutions comprising cupric chloride and hyrdrochloric acid from the copper etching process are regenerated by a process in which the acid is subjected to distillation with sulfuric acid. In one embodiment, the process comprises (a) providing a spent etchant comprising at least about 10% by weight chloride and at least about 5% dissolved copper; (b) adding at least about 2 moles of sulfuric acid per mole of dissolved copper to the spent etching solution, thereby converting copper chloride into hydrochloric acid and precipitated copper sulfate; (c) distilling the mixture from step (b) to vaporize at least a portion of the hydrochloric acid; (d) condensing at least a portion of the vaporized hydrochloric acid; (e) separating at least a portion of the precipitated copper sulfate from the residual liquid, wherein said residual liquid comprises sulfuric acid; and (f) reusing at least a portion of the residual liquid as a sulfuric acid source in step (b).

Abstract: The natural gas is deacidized by contacting in zone 3 with a solvent containing amine in aqueous solution. The gas is then dehydrated by contacting in zone 4 with a solvent very rich in amine. After the contacting operations, the solvent containing H2S. and water is expanded in drum 9, then regenerated in column 11. Part of the regenerated solvent is sent to zone 3. Another part of the regenerated solvent is vacuum distilled in column 18 so as to produce an amine-rich solvent that is sent to zone 4.

Abstract: The current invention provides systems and method for reducing emissions of gaseous pollutants such as carbon monoxide, nitric oxide and nitrogen dioxide. The invention utilizes at least one catalyst bed and at least one fluidizable bed of sorbent material. The current invention provides for regeneration of the sorbent material without interrupting the catalytic reaction.

Abstract: The invention provides a catalyst structure for catalytic reduction of nitrogen oxides in exhaust gases by supplying and subjecting fuel to combustion with periodic rich/lean excursions and contacting the resulting exhaust gases with the catalyst structure, wherein the catalyst structure comprises, on an inactive substrate: (A) an outer catalyst layer comprising an outer layer catalyst component wherein the outer layer catalyst component comprises a first catalyst component comprising a mixture or a composite oxide (except mixtures or composite oxides of cerium oxides and zirconium oxides) of (a) ceria and (b) at least one oxide of at least one element selected from zirconium, gadolinium, terbium, samarium and lanthanum, and a second catalyst component comprising (c) at least one catalyst component selected from rhodium, palladium and their oxides, and (B) an inner catalyst layer comprising an inner layer catalyst component wherein the inner layer catalyst component comprises (a) at least one catalyst co

Abstract: The present invention provides a method enabling the high purification of a niobium compound and/or tantalum compound in a simplified manner at a low cost. This is accomplished by providing a method enabling the high purification of a niobium compound and/or tantalum compound comprising the steps of preparing a solution containing niobium and/or tantalum, allowing a precipitate comprising niobium and/or tantalum to develop, separating the precipitate by filtration from the filtrate, converting the precipitate to a liquid melt or taking the filtrate, and separating a niobium compound from a tantalum compound or vice versa by utilizing the difference in solubility to the solvent between the niobium compound and the tantalum compound.

Abstract: A process and apparatus for the manufacture of high-strength, low-salt sodium hypochlorite. An aqueous solution that comprises certain weight percentages of sodium hypochlorite and sodium hydroxide and that is essentially free of sodium chloride (salt) crystals, an aqueous solution that comprises a certain weight percentage of sodium hydroxide, and chlorine in gas and/or liquid phase that may or may not include inerts are reacted in a tank. This creates a solution having a precipitation zone where salt crystals are precipitating out of solution and falling downward to form a slurry, some of which is withdrawn, then cooled, and then re-introduced into the precipitation zone. Above the precipitation zone is a crystal-free mother liquor zone consisting essentially of crystal-free mother liquor containing a weight percentage of sodium hypochlorite greater than that of than the lower strength aqueous sodium hypochlorite bleach being reacted.

Abstract: Titania is dissolved in a hydrogen peroxide solution to produce an amorphous titania gel, then the amorphous titania gel and a hydrogen peroxide solution are mixed together to produce an amorphous titania sol, and then an alkali solution is supplied to the solution containing the amorphous titania sol to thereby adjust a pH of the solution to 2 to 10. Even if the obtained solution containing amorphous titania is, for example, left to stand at normal temperature for a long time, gelling or aggregation of titania can be suppressed. That is, it is possible to obtain a titania solution that can maintain the state where fine particles of titania are highly dispersed in the solution, over a long term.

Abstract: Disclosed herein is a hydrogen storage composition comprising a catalyst composition disposed upon a storage composition; wherein the catalyst composition comprises an alloy of calcium, barium, platinum, palladium, nickel, titanium, chromium, manganese, iron, cobalt, copper, silicon, germanium, rhodium, rhodium, ruthenium, molybdenum, niobium, zirconium, yttrium, barium, lanthanum, hafnium, tungsten, rhenium, osmium, iridium, or a combination comprising at least one of the foregoing metals.

Abstract: A process for producing a fuel gas for a fuel cell is provided. The process includes a step of converting hydrocarbons and/or oxygen-containing hydrocarbons to a reformed gas which is composed principally of hydrogen by an autothermal reforming reaction using an autothermal reforming catalyst. The catalyst includes rhodium supported on a support containing 5 to 40 percent by mass of a cerium oxide or rare earth element oxide which is composed principally of a cerium oxide, 60 to 95 percent by mass of an aluminum oxide, and 0 to 10 percent by mass in terms of metal of one or more elements selected from the group consisting of an alkaline metal and an alkaline earth metal, the atomic ratio of cerium and rhodium (Ce/Rh) being 1 to 250.

Abstract: Compounds that modulate natural ? amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a ? amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3–5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a ? amyloid peptide, preferably a retro-inverso isomer of A?17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups include cyclic, heterocyclic, polycyclic and branched alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an alkyl amide group, an aryl amide group or a hydroxy group.

Abstract: The present invention relates to a contrast-enhanced diagnostic imaging method for monitoring the efficacy of interventional therapies. The contrast agents useful in this method comprise an image-enhancing moiety (IEM) and a state-dependent tissue binding moiety (SDTBM). These contrast agents exhibit state-dependent binding to one or more components of a targeted tissue or tissue component and provide a detectable change in the signal characteristics of the agent once bound to the targeted tissue. As a result, these agents exhibit a binding affinity for, and thus image contrast of, the targeted tissue which changes as the tissue-state changes during therapy.

Abstract: The use of radio-labeled antitumor drugs in the treatment of solid tumors by the method of administering a radio-labeled anticancer drug to a patient and imaging at least a part of the patient using Positron Emission Tomography imaging is described. The method can be used to monitor delivery of antitumor drugs to tumors, to predict the effectiveness of therapy with a particular antitumor drug or combination of antitumor drugs, to assess the effectiveness of modulators of cellular accumulation, to individualize therapy and to evaluate the effectiveness of antitumor drugs with respect to particular cancers. Particularly preferred drugs are labeled taxanes, e.g., 11C-paclitaxel and 11C-docetaxel, labeled anthracyclines, e.g., 11C-doxorubicin and 11C-epirubicin, and other radiolabeled drugs, e.g. 11C-topotecan, 11C-SN-38, and 11C-imatinib. The invention further describes antitumor drugs labeled with the radioactive label 11C and methods of preparing radio-labeled drugs.

Abstract: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo.

Abstract: Aqueous dispersions of crystalline polymers based on hydrophobic monomers, preferably on a mixture of hydrophobic and hydrophilic monomers which contains a crosslinking monomer, particularly side chain crystalline (SCC) polymers. The dispersions are useful for providing coatings on substrates, particularly on seeds (whose dormancy is thus extended) and on fibrous substrates, particularly human hair (which thus becomes heat-settable).

Abstract: A glass composition having the general empirical formula given below, expressed in weight percent of the element: P: 16–24, F: 5–30, O: 20–40 and at least one of Na, K, Li or Al in an amount up to a total of 40 wt. % and optionally, up to 5 wt. % of boron and/or silicon. The composition may be used for the treatment and/or prevention of dental caries by providing a slow fluoride releasing device that may be attached to a tooth to release fluoride into the saliva or an individual.

Abstract: The present invention relates to a sunscreen formulation which exhibits superior ultraviolet protection and water resistance than prior art sunscreen compositions. The sunscreen formulation comprises (a) a dispersion comprising a sunscreen active agent and (b) a base composition comprising a rheological modifying agent and water. The sunscreen formulation is substantially free of surfactants. According to a preferred embodiment, the sunscreen active agent is ethylhexylmethoxycinnamate, butylmethoxydibenzoylmethane, or a combination thereof. The sunscreen formulation preferably comprises a phosphorylated starch derivative as a rheological modifying agent. Another embodiment of the present invention is a method of protecting skin or hair from ultraviolet radiation by applying an effective amount of the sunscreen formulation of the present invention to the skin or hair.

Abstract: A cosmetic water-in-oil composition is provided which includes a water-in-oil emulsifying silicone surfactant, an ultrafine titanium dioxide and conjugated linoleic acid. The presence of conjugated linoleic acid stabilizes the composition against color degradation and also maintains an approximately steady viscosity.

Abstract: A cosmetic water-in-oil composition is provided which includes a water-in-oil emulsifying silicone surfactant, crosslinked silicone elastomer and conjugated linoleic acid. The conjugated linoleic acid functions to improve radiance on facial surfaces to which the composition is topically applied.

Abstract: Novel methods and compositions for treating aged and environmentally damaged skin are disclosed which provide improvements in the skin's visual appearance, function and clinical/biophysical properties by activating at least one proteolytic enzyme in the skin's stratum corneum. The disclosed treatment methods involve topical application of a novel cosmetic composition containing a combination of a cationic surfactant such as N,N,-dimethyldodecyl amine oxide (DMDAO), an anionic surfactant such as sodium dodecyl sulfate (SDS), or monoalkyl phosphate (MAP) and a chelating agent such as ethylene diamine tetraacetate (EDTA) to stimulate a chronic increase in the replacement rate of the skin's stratum corneum by means of corneum protease activation. This chronic, low level stimulation is effective to induce repair and replacement of the stratum corneum, epidermis, and dermis of the skin and improvements in the appearance, function, and anti-aging properties of the skin.

Abstract: The invention provides a method of treating or preventing a pathologic state in a mammal. The method comprises administering to the mammal a promoter of T-cell expansion and an inducer of CD40 stimulation, wherein CD40 is stimulated on cells of the immune system. The promoter of T-cell expansion and inducer of CD40 stimulation are administered in synergistically effective amounts to treat or prevent the pathologic state in the mammal. The invention also provides a method of assessing the effectiveness of treatment of a pathologic state in a mammal, wherein the mammal has been administered a promoter of T-cell expansion and an inducer of CD40 stimulation, wherein CD40 is stimulated on cells of the immune system.

Abstract: This invention provides medicaments and methods for managing cancer using donor cells that are alloactivated in culture. Alloactivated cells are implanted into the bed of a solid tumor and initiate a response by the host against the tumor. Subsequently, alloactivated cells are implanted into the bed of a solid tumor a second time. The two implants work synergistically to confer remarkable benefit to the treated subject, both in terms of management of the cancer and the development of an anti-cancer immune response. The beneficial effects may include regression of the tumor and extended survival. Removal of any residual tumor after the second implant facilitates ongoing resistance to tumor regrowth or metastasis.

Abstract: The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such as angiostatin or parts thereof, and transplanting the recombinant vector or a cell that is transfected or transduced with the recombinant vector into the affected area of a patient, and also provides the compositions for the gene therapy. The compositions for the gene therapy according to the present invention can be used effectively for the treatment of rheumatoid arthritis, for which effective treating methods have not been developed until now, by providing the anti-angiogenic proteins into the knee of a patient continuously to prevent the synovial tissue hyperplasia and the resulting inflammation.

Abstract: An improved tissue graft construct comprising submucosa of a warm-blooded vertebrate and a preselected group of eukaryotic cells are described. The improved tissue graft constructs can be used in accordance with the present invention to enhance the repair of damaged or diseased tissues in vivo.

Abstract: The invention features methods of promoting hair growth in a subject. The methods include inducing or mimicking the effects of Wnt promoted signal transduction, e.g., by increasing the level of Wnt protein or administering an agent which mimics an effect of Wnt promoted signal transduction, e.g., by administering lithium chloride. Methods of inhibiting hair growth are also provided.

Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

Abstract: The invention features methods of modulating fibrosis and/or angiogenesis by inhibiting components of the VEGF signaling pathway. The methods are useful in the treatment of fibrotic and or angiogenesis related disorders.

Abstract: Disclosed herein are monoclonal antibodies (Mabs) against ricin toxin and its subunits. The Mabs were initially selected based upon their ability to bind to ricin and its individual subunits in a solid-phase enzyme-linked immunoassay (ELISA). Several candidates were selected for further evaluation, including their ability to inhibit ricin intoxication in vitro and for their utility as immunodiagnostic reagents. As disclosed herein, the Mabs may be used in immunoassays. Also disclosed, are use of the Mabs to inhibit ricin-mediated eukaryotic cell cytotoxicity in vitro, thereby indicating that these Mabs may be used to prevent and treat ricin intoxication in vivo. Kits comprising the Mabs are also disclosed.

Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies, or B7.1-binding fragments thereof, may be used for the treatment of Crohn's disease.

Abstract: The present invention provides methods to produce toxoid vaccines, such as ricin A chain vaccines, with reduced ability to promote vascular leak syndrome (VLS) and catalytic toxicity associated with various proteinaceous toxins, such as ribosome inactivating proteins. The invention also provides toxoids which have been mutated to lack amino acid sequences which induce VLS and toxic catalytic activity.

Abstract: This invention relates to nectin polypeptides and polynucleotides, to methods of making such polypeptides and polynucleotides, and to methods of using such polypeptides and polynucleotides to modulate cell adhesion, cell migration, and angiogenesis, to treat conditions related to cell adhesion including endothelial and epithelial cell proliferation, migration, and barrier function, and to identify agents that alter nectin polypeptide activities.

Abstract: A formulation comprising molecular arrangements capable of penetrating pores in a barrier, owing to penetrant adaptability, despite the fact that the average diameter of said pores is smaller than the average penetrant diameter, provided that the penetrants can transport agents or else enable agent permeation through the pores after penetrants have entered pores, characterized in that the formulation comprises at least one consistency builder in an amount that increases the formulation to maximally 5 Nm/s so that spreading over, and retention at, the application area is enabled and/or at least one antioxidant in an amount that reduces the increase of oxidation index to less than 100% per 6 months and/or at least one microbicide in an amount that reduces the bacterial count of 1 million germs added per g of total mass of the formulation to less than 100 in the case of aerobic bacteria, to less than 10 in the case of entero-bacteria, and to less than 1 in the case of Pseudomonas aeruginosa or Staphilococcus aur

Abstract: The subject of the present invention is a fungicidal composition useful for the treatment of fungal diseases of crops and which comprises in particular at least one vegetable oil with high siccative power, as well as a method of treating crops using such a composition.

Abstract: The invention relates to a process for producing an implant, with the implant possessing a textured foreign structure. A porous protein matrix is at least partially anchored in the textured foreign structure, with the porous protein matrix possessing a directional pore structure.

Abstract: This invention provides for a therapeutic system for timed and controlled release of at least one therapeutic active agent to a human or animal organism by diffusion through the skin or mucous membrane. The active agent is initially present, for the purposes of manufacture and storage, in a first state in the form of a pharmaceutically acceptable salt, which is chemically stable and insufficiently permeable for the skin or mucous membrane. The active agent is converted at the application site upon access of moisture and by an activating agent into a second state, which is suitable for diffusion through the skin or mucous membrane and in which it is taken up by the organism. The activating agent is initially present as a solid substance or a mixture or a plurality of such substances, which reacts in aqueous solution as an acid or base. The activating agent contains a portion of water of at least 5% in its solid body structure, either intercalated or bound thereto.

Abstract: The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

Abstract: Compositions comprising ziprasidone free base or a difficult to wet pharmaceutically acceptable ziprasidone acid addition salt, a polysorbate, and colloidal silicon dioxide form good aqueous suspensions having a useful shelf life and are easily re-suspended if setting occurs.